![](data:image/svg+xml;charset=utf-8,<svg height="32" width="135" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="16" width="68" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="18" width="8" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="15" width="18" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="15" width="15" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="675" width="1200" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
(PTI) Dr Reddy's Laboratories on Wednesday reported a 77 per cent increase in its consolidated net profit at ₹1,247 crore in the third quarter ended December 31, 2022.
The drug firm had reported a net profit of ₹706 crore in the October-December period of the previous fiscal.
Revenue from operations rose to ₹6,770 crore during the period under review as against ₹5,320 crore in the year-ago period, Dr Reddy's Laboratories said in a regulatory filing.
What is EBITDA
First Published: 25 Jan 2023, 05:17 PM IST